NZ241398A - Influenza vaccine containing influenza virus core particles as an additive - Google Patents

Influenza vaccine containing influenza virus core particles as an additive

Info

Publication number
NZ241398A
NZ241398A NZ241398A NZ24139892A NZ241398A NZ 241398 A NZ241398 A NZ 241398A NZ 241398 A NZ241398 A NZ 241398A NZ 24139892 A NZ24139892 A NZ 24139892A NZ 241398 A NZ241398 A NZ 241398A
Authority
NZ
New Zealand
Prior art keywords
core
vaccine
protein
composition according
additive
Prior art date
Application number
NZ241398A
Other languages
English (en)
Inventor
Catherine Moste-Deshairs
Bernard Meignier
Original Assignee
Pasteur Merieux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9409015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ241398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Merieux filed Critical Pasteur Merieux
Publication of NZ241398A publication Critical patent/NZ241398A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ241398A 1991-01-24 1992-01-24 Influenza vaccine containing influenza virus core particles as an additive NZ241398A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9100806A FR2671974A1 (fr) 1991-01-24 1991-01-24 Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal.

Publications (1)

Publication Number Publication Date
NZ241398A true NZ241398A (en) 1994-08-26

Family

ID=9409015

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ241398A NZ241398A (en) 1991-01-24 1992-01-24 Influenza vaccine containing influenza virus core particles as an additive

Country Status (10)

Country Link
EP (1) EP0522138B2 (enrdf_load_stackoverflow)
AT (1) ATE234861T1 (enrdf_load_stackoverflow)
AU (1) AU654699B2 (enrdf_load_stackoverflow)
CA (1) CA2078985C (enrdf_load_stackoverflow)
DE (1) DE69232962T3 (enrdf_load_stackoverflow)
FR (1) FR2671974A1 (enrdf_load_stackoverflow)
IL (1) IL100765A (enrdf_load_stackoverflow)
NZ (1) NZ241398A (enrdf_load_stackoverflow)
WO (1) WO1992013002A1 (enrdf_load_stackoverflow)
ZA (1) ZA92510B (enrdf_load_stackoverflow)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019013A1 (en) * 1993-02-19 1994-09-01 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
WO1998046262A1 (en) * 1997-04-16 1998-10-22 Connaught Laboratories, Inc. Anti-influenza compositions supplemented with neuraminidase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2483779A1 (fr) * 1980-06-05 1981-12-11 Synthelabo Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins
GB8502096D0 (en) * 1985-01-28 1985-02-27 Medical Res Council Influenza vaccine
US5136019A (en) * 1989-05-24 1992-08-04 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use

Also Published As

Publication number Publication date
DE69232962T2 (de) 2005-06-23
ZA92510B (en) 1992-11-25
EP0522138B1 (fr) 2003-03-19
IL100765A (en) 1996-06-18
AU654699B2 (en) 1994-11-17
DE69232962T3 (de) 2007-11-08
CA2078985C (fr) 2004-11-09
FR2671974A1 (fr) 1992-07-31
AU1248792A (en) 1992-08-27
WO1992013002A1 (fr) 1992-08-06
CA2078985A1 (fr) 1992-07-25
EP0522138A1 (fr) 1993-01-13
IL100765A0 (en) 1992-09-06
FR2671974B1 (enrdf_load_stackoverflow) 1995-03-03
DE69232962D1 (de) 2003-04-24
ATE234861T1 (de) 2003-04-15
EP0522138B2 (fr) 2007-02-14

Similar Documents

Publication Publication Date Title
Beare et al. Replication of avian influenza viruses in humans
Bungener et al. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection
US6485729B1 (en) Neuraminidase-supplemented compositions
Johnson et al. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine
Eliasson et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine
US6743900B2 (en) Proteosome influenza vaccine
AU763210B2 (en) Novel influenza virus vaccine composition
US6048536A (en) Vaccine compositions
Jones et al. Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (iscoms)
Glathe et al. Comparison of humoral immune responses to trivalent influenza split vaccine in young, middle-aged and elderly people
Barchfeld et al. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice
WO1998046262A1 (en) Anti-influenza compositions supplemented with neuraminidase
Wong et al. A single dose of whole inactivated H7N9 influenza vaccine confers protection from severe disease but not infection in ferrets
Pushko et al. Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus
US4029763A (en) Influenza vaccine containing purified neuraminidase antigen and method of using the same
Ben Ahmeida et al. The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMS, with FCA, ALH or as infectious virus
Ainai et al. Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine
Webster et al. Matrix protein from influenza A virus and its role in cross-protection in mice
US5741493A (en) Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive
Liew et al. Induction and characterization of delayed‐type hypersensitivity to influenza virus in mice
Potter et al. A new surface-antigen-adsorbed influenza virus vaccine II. Studies in a volunteer group
AU654699B2 (en) Influenza virus vaccine composition having a synergistic effect and containing influenza virus core as an additive
CN109180784B (zh) 一种促进禽流感和/或新城疫疫苗的免疫反应的法氏囊活性六肽及应用
Romanova et al. Interference between cold-adapted (ca) influenza A and B vaccine reassortants or between ca reassortants and wild-type strains in eggs and mice
Katz et al. Recognition of influenza virus hemagglutinin by subtype-specific and cross-reactive proliferative T cells: contribution of HA1 and HA2 polypeptide chains.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired